Search results
Results from the WOW.Com Content Network
Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD. Editas (EDIT) Up More Than 100% ...
In 2004, i.e. in the early years of Espacenet, Nancy Lambert considered that, although free, Espacenet, like the United States Patent and Trademark Office (USPTO) database of US patents, "still tend[ed] to have primitive search engines and in some cases rather cumbersome mechanisms to download patents."
Wikipedia entry for Google Patents.Google Patents is a search engine from Google that indexes patents and patent applications from the United States Patent and Trademark Office.
Patent Application Information Retrieval (PAIR) is an online service provided by the United States Patent and Trademark Office to allow users to see the prosecution histories of United States patents and patent applications and obtain copies of documents filed therein. There are two services: Public PAIR, which allows the general public to ...
Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.
The European Patent Bulletin is a weekly trilingual publication of the European Patent Office (EPO), generally issued every Wednesday. [1] It contains "entries made in the Register of European Patents, as well as other particulars, the publication of which is prescribed by [the European Patent Convention (EPC)] or its implementation". [2 ...
IP5 is a forum of the five largest intellectual property offices in the world. The five patent offices are the US Patent and Trademark Office (USPTO), the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), and the National Intellectual Property Administration (CNIPA formerly SIPO) in China.
Here's the story behind the biotech stock that could be the best way to profit from the discovery of the century: CRISPR-Cas9 gene editing.